Target intelligence / Profile preview

Transmembrane ascorbate-dependent reductase cytochrome b561 (CYB561)

Target
CYB561
Molecular classification
Enzyme, Transmembrane electron transporter, Ferric-chelate reductase
01

Overview

Transmembrane ascorbate-dependent reductase cytochrome b561 (CYB561) is a multipass transmembrane enzyme that functions as an electron transporter, predominantly located in the membranes of secretory vesicles, such as chromaffin granules in neuroendocrine tissues[1][2][3]. This protein is involved in the transfer of electrons from cytosolic ascorbate (vitamin C) to intravesicular substrates, including iron (ferric chelates) and peptide-processing enzymes, thereby enabling enzymatic activities essential for neurotransmitter and peptide hormone biosynthesis (e.g., dopamine to norepinephrine conversion via dopamine-beta-hydroxylase)[1][2][3]. Structurally, it is composed of 273 amino acids with six transmembrane domains and two non-covalently bound heme groups that mediate electron transport[1][2][3]. CYB561 represents a distinct family of eukaryotic electron transfer enzymes and plays a key role in ascorbate recycling and iron absorption[3]. It is highly expressed in nervous and neuroendocrine tissues, such as the adrenal medulla and brain, but not in most peripheral organs[2]. No drugs are currently known to specifically target this protein, and no safety concerns or clinical biomarkers have been established for CYB561 as of current knowledge.

Other names
Transmembrane ascorbate-dependent reductase CYB561ferric-chelate reductase 2chromaffin granule cytochrome b561CGCytbcytochrome b-561cytochrome b561 family member A1FRRS2CYB561A1ORTHYP2
02

Mechanism of action

Substrate-mediated electron transfer from ascorbate to membrane-bound heme groups; Reduction of intravesicular ferric iron (Fe³⁺) to ferrous iron (Fe²⁺); Supply of reducing equivalents to enzymes (dopamine-beta-hydroxylase, peptide amidase)

03

Biological functions

Electron transport across membranesAscorbate (vitamin C) recyclingIron absorption (ferric-chelate reduction)Reducing equivalents supply for vesicular enzymes (e.g., dopamine-beta-hydroxylase, alpha-peptide amidase)
04

Disease associations

Other (e.g., deficiencies in iron absorption and catecholamine metabolism may be implicated)

Beyond the preview

Go deeper on Transmembrane ascorbate-dependent reductase cytochrome b561 (CYB561).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane ascorbate-dependent reductase cytochrome b561 (CYB561).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call